The RNA vaccine uses an experimental approach that involves injecting part of the virus’ genetic code
The first effective coronavirus vaccine has been developed by American pharmaceutical giant Pfizer and German technology company BioNTech, it is being widely reported in the media. The revolutionary new RNA vaccine technology, which has been tested on 43,500 people in six countries and has no safety concerns so far, is more than 90% effective, trails have shown. Of the dozen or so vaccines in the final phase 3 stage testing, this is the first to show results and the developers plan to apply for emergency approval to use the vaccine by the end of the month. Two doses, three weeks ap...
To continue reading this article...
Join COVER for free
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.